Regulatory and health technology assessment of cell and gene therapies in Europe: Convergence or divergence?

Mark Hoogendoorn; Babs Fabriek; Lourens T. Bloem

Regulatory and health technology assessment of cell and gene therapies in Europe: Convergence or divergence?

Mark Hoogendoorn, Babs Fabriek, Lourens T. Bloem

Utrecht University

Research output: Contribution to journal › Meeting Abstract › Other research output

Original language	English
Pages (from-to)	16-16
Number of pages	1
Journal	Pharmacoepidemiology and Drug Safety
Volume	32
Publication status	Published - Oct 2023

Cite this

@article{fad7bc90c5e94e75a22e352ca245cbb5,

title = "Regulatory and health technology assessment of cell and gene therapies in Europe: Convergence or divergence?",

author = "Mark Hoogendoorn and Babs Fabriek and Bloem, {Lourens T.}",

year = "2023",

month = oct,

language = "English",

volume = "32",

pages = "16--16",

journal = "Pharmacoepidemiology and Drug Safety",

issn = "1053-8569",

publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Regulatory and health technology assessment of cell and gene therapies in Europe

T2 - Convergence or divergence?

AU - Hoogendoorn, Mark

AU - Fabriek, Babs

AU - Bloem, Lourens T.

PY - 2023/10

Y1 - 2023/10

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=d7dz6a2i7wiom976oc9ff2iqvdhv8k5x&SrcAuth=WosAPI&KeyUT=WOS:001091511700027&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

SN - 1053-8569

VL - 32

SP - 16

EP - 16

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

ER -

Regulatory and health technology assessment of cell and gene therapies in Europe: Convergence or divergence?

Other files and links

Cite this